行情

TNXP

TNXP

Tonix医药控股
NASDAQ

实时行情|Nasdaq Last Sale

1.140
+0.249
+27.99%
盘后: 1.110 -0.03 -2.63% 19:55 08/13 EDT
开盘
0.8940
昨收
0.8907
最高
1.160
最低
0.8920
成交量
2,328.52万
成交额
--
52周最高
5.89
52周最低
0.3902
市值
1.49亿
市盈率(TTM)
-0.0166
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TNXP价格均价为2.375,最高价位2.500,最低价为2.250。

EPS

TNXP 新闻

更多
Tonix Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Highlights
GlobeNewswire · 3天前
Tonix Pharmaceuticals Q2 EPS $(0.23) Up From $(0.95) YoY
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(0.23) per share. This is a 75.79 percent increase over losses of $(0.95) per share from the same period last year.
Benzinga · 3天前
Tonix Pharma on go with study of TNX-102 SL in alcohol use disorder
The FDA has signed off on a Phase 2 proof-of-concept study evaluating Tonix Pharmaceuticals' (TNXP +6.0%) TNX-102 SL for the treatment of alcohol use disor
seekingalpha · 08/06 18:43
Tonix Pharmaceuticals Announces Clearance of IND for TNX-102 SL for Treatment of Alcohol Use Disorder
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New D
GlobeNewswire · 08/06 13:00
Tonix Pharma meets Nasdaq minimum bid price requirement
Tonix Pharmaceuticals (TNXP) regains compliance with the minimum bid price requirement for continued listing on the NASDAQ Global Market. On August 3, the
seekingalpha · 08/04 20:17
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
GlobeNewswire · 08/04 14:00
Tonix Pharma Reports Regained Compliance With Nasdaq Minimum Bid Price Requirement
Benzinga · 08/04 13:04
Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference
GlobeNewswire · 08/04 12:00

所属板块

生物技术和医学研究
+0.99%
制药与医学研究
-0.06%

热门股票

代码
价格
涨跌幅

TNXP 简况

Tonix Pharmaceuticals Holding Corp.是一家临床阶段的制药公司。该公司的药物开发项目针对中枢神经系统(CNS)疾病,包括纤维肌痛(FM)和创伤后应激障碍(PTSD)。该公司致力于开发一系列候选产品,包括一个处于临床开发阶段的候选产品,该候选产品用于两种注册适应症。TNX-102 SL(环苯扎林盐酸(HCl)舌下片)是通过舌下给药的含有环苯扎林(CBP)的崩解片。该公司已完成TNX-102 SL的第二b阶段BESTFIT试验,以治疗FM。该公司正在对TNX-102 SL在第三阶段AFFIRM研究中进行评估,以治疗FM。该公司还正在开展TNX-102 SL的第二阶段AtEase临床试验,以治疗军事相关PTSD。 该公司还拥有其他候选产品,包括固定剂量联合药物产品(CDP)TNX-301。
展开

微牛提供Tonix Pharmaceuticals Holding Corp(NASDAQ-TNXP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TNXP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TNXP股票基本功能。